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Liver function tests do not always normalize after successful surgical attenuation of
portosystemic shunts (PSS). Currently the gold standard to demonstrate absence of
portosystemic shunting is portal scintigraphy. Serum hyaluronic acid concentrations (sHA) in
dogs with PSS are increased compared to those in healthy dogs. A preliminary study
reported that sHA decreased 2 weeks after surgical attenuation of extrahepatic PSS
(EHPSS).
The aims of the current study were: 1/ to serially evaluate sHA in dogs with surgically
attenuated EHPSS and to determine differences in sHA in dogs with closed versus open
(persistent or multiple acquired) PSS; 2/ to compare sHA in patients with EHPSS versus
other liver diseases.
Twenty dogs with surgically treated EHPSS and 10 dogs with other liver diseases were
included. Dogs with EHPSS had a blood sample taken at diagnosis, 1, 3 and 6 months
postoperatively. At the 3-month control visit a transsplenic portal scintigraphy was performed
to determine shunt closure status. Dogs with other liver diseases were only sampled at a
single time point and comprised of: Maltese dogs with moderately increased postprandial bile
acids and no liver disease based on imaging (n = 3), dogs with histologically confirmed portal
vein hypoplasia (n = 4) or histologically confirmed chronic hepatitis (n = 3). All samples were
analysed in batch using a commercially available ELISA kit (Hyaluronan Quantikine, R&D
systems, Minneapolis).
At EHPSS diagnosis, median sHA was 337.20 ng/mL (158.02-790.66 ng/mL). After
successful surgery (closed PSS), sHA dropped to 36.62 ng/mL (13.51-92.24 ng/mL) whereas
in dogs with persistent portosystemic shunting, sHA remained higher (median 135.70 ng/mL;
56.44-312.04 ng/mL). Kruskal-Wallis tests revealed a significant difference between sHA in
dogs with closed versus open EHPSS (P= 0.008,P= 0.005 and P= 0.025 at 1, 3, and 6
months postoperatively, respectively). The median sHA of dogs with other liver diseases was
119.64 ng/mL (48.44-160.00 ng/mL),which was significantly lower compared to dogs at the
moment of EHPSS diagnosis (P= 0.009).
In dogs with EHPSS, sHA seems to be a promising non-invasive biomarker to determine
EHPSS closure after surgical attenuation. In addition, it might also be valuable to differentiate
dogs with EHPSS from dogs with other liver diseases.
